Venrock

What Venrock does

Venrock is a US-based venture capital firm founded in 1969, headquartered in Palo Alto, California, with additional offices in New York and Boston. It operates two distinct investment programs: a traditional early-stage venture capital program investing in technology and healthcare companies from Seed through Series B+, and a separate later-stage program called Venrock Healthcare Capital Partners (VHCP), operated at venrockcp.com, which applies a venture-style long-duration approach to small-cap public and late-stage private healthcare companies. The firm invests in sectors including AI/ML, SaaS, FinTech, Consumer, Developer Infrastructure, Cybersecurity, Defense & Aerospace, Biotechnology, Pharmaceuticals, Life Science Tools, and Health Tech, with a portfolio exceeding 100 companies and notable alumni such as Apple (since 1978), Intel, Illumina, Cloudflare, 10X Genomics, athenahealth, Lucid Motors, REGENXBIO, and Gilead Sciences.

The firm does not develop proprietary technology products; its operational infrastructure consists of investment management systems, an eFront LP portal, a corporate website with a Companies showcase, the Running Through Walls podcast, an AI Strategy content hub, and newsletter distribution. It is staffed by approximately 50+ team members across Investment Team, Portfolio Advisory Committee, Finance, Legal/Compliance, Marketing, Talent, IT, and Support functions. The investment team includes domain-specialized Partners in SaaS/Enterprise & AI (Brian Ascher), AI/Compute/Defense (Ethan Batraski, Nick Beim), Biotechnology/Pharma (Racquel Bracken, Phil DiGiacomo, Mariana Mihalusova), Health Tech (Bob Kocher, Bryan Roberts, Siobhan Nolan Mangini), and Enterprise/Mobile (Mike Tyrrell, Boston), with a separate VHCP team and an external Portfolio Advisory Committee.

Venrock's revenue model is conventional for venture capital: it earns capital appreciation and exit proceeds (IPOs and M&A) on portfolio holdings, supplemented by management fees on funds it manages. The firm does not publicly disclose management fees, carried interest, or fund economics, and its website explicitly states that materials are not offers or solicitations. Deal flow is sourced primarily through proprietary partner networks, direct founder outreach, and syndicate relationships with co-investors such as Bain Capital Ventures, Battery Ventures, Highland Europe, Insight, Meritech, and Frazier Life Sciences.

Name

Venrock

Legal name

Venrock Associates

Website

https://venrock.com

Company type

Private

Founded year

1978

Operating status

Operating

Headcount range

101–250 employees

Short description

Venrock is a US venture capital firm (founded 1969, Palo Alto) operating two programs — an early-stage tech and healthcare venture program and a later-stage Crossover/Public Healthcare program (VHCP) — investing across Seed through Series B+ and managing 100+ portfolio companies.

Ownership category

akta.pro rank

Product category

Venture Capital

NAICS

Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro primary industry

Corporate Venture Capital (CVC) (FSANAAAF)

akta.pro secondary industry

Joint Venture CVC / Consortium Funds (Multi-corporate) (FSANAHAE)

Keywords

• Venture capital investing
• Early-stage technology investments
• Healthcare venture capital
• Crossover public healthcare
• Biotech growth equity

Headquarters

HQ city

Palo Alto

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Venture capital fund investments: Operates two investment programs: an early-stage venture capital program focused on healthcare and technology, and a later-stage Crossover/Public Healthcare program (VHCP) for small-cap public and late-stage private healthcare companies. Returns are generated via capital appreciation and exits (IPOs and M&A) on portfolio holdings; the firm does not publicly disclose management fees or carried interest terms.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

Venrock is a private venture capital firm that deploys risk capital into early-stage technology and healthcare companies from Seed through Series B+ stages. It operates two distinct investment programs: a traditional early-stage venture capital program spanning AI/ML, SaaS, FinTech, Consumer, Developer Infrastructure, Therapeutics, Health Tech, Life Science Tools, and Medical Devices, and a separate later-stage Crossover/Public Healthcare program (VHCP) that applies a venture-style long-term approach to small-cap public and late-stage private healthcare companies.

Product overview

Venrock is a venture capital firm — not a software product company — and its "offerings" are organized as two distinct investment programs plus a small set of content/media properties. The primary offering is the traditional Venture Capital Program, which makes early-stage investments across healthcare and technology (with sub-sectors including AI, FinTech, Consumer, Developer Infrastructure, Therapeutics, Health Tech, Life Science Tools, and Medical Devices), supporting portfolio companies such as Archetype AI, Astronomer, Altruist, 6sense, Dataminr, Cloudflare, Apple, and Intel. The second offering is Venrock Healthcare Capital Partners (VHCP), a separate later-stage healthcare program (operating at venrockcp.com) that applies a venture capital-like long-term approach to small-cap public and late-stage private healthcare companies. In addition to these two investment programs, Venrock publishes thought-leadership content including the "Running Through Walls" podcast and an AI Strategy content hub on venrock.com, which together complement the firm's investment activities with brand-building and founder/enterprise education.

Differentiator

Problem solved

Functional benefit

Brands

• Venrock Crossover / Public Healthcare (VHCP): Later-stage healthcare investment program operated through venrockcp.com, focused on small-capitalization public companies and late-stage private healthcare companies using a venture capital-like long-term approach.

Products and services

• Traditional Venture Capital Program Early-stage venture capital program investing in healthcare and technology companies across AI/ML, SaaS, FinTech, Consumer, Developer Infrastructure, Therapeutics, Health Tech, Life Science Tools, and Medical Devices. Capital is provided at Seed, Series A, and Series B+ stages to founders building technology and healthcare companies.
• Venrock Healthcare Capital Partners (VHCP / Crossover/Public Healthcare Program) Later-stage healthcare investment program that applies a venture capital-like long-term approach to small-capitalization public healthcare companies and late-stage private healthcare companies. Operates through a dedicated website (venrockcp.com) and is staffed by a distinct VHCP team.

Quantifiable outcome

• Apple investment since 1978 grew into one of the world's largest publicly traded companies (NASDAQ: AAPL).
• +5 more outcomes

Named customers12 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators6 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Andreessen Horowitz (a16z): US-based venture capital firm investing across technology and healthcare stages with a multi-fund, multi-strategy structure similar to Venrock's two-program approach. a16z operates Bio + Health and general tech funds that directly compete with Venrock for the same founder-led deal flow in AI, biotech, and FinTech.
• Sequoia Capital: Palo Alto-based early- and growth-stage venture capital firm with deep healthcare and technology franchises, including the well-known Apple investment lineage that parallels Venrock's heritage. Sequoia competes with Venrock across seed, Series A, and later stages in software, biotech, and healthcare technology.
• New Enterprise Associates (NEA): Large, multi-stage US venture capital firm with healthcare and technology practices operating across seed through growth stages. NEA's healthcare franchise and size are closely comparable to Venrock's combined early-stage and VHCP capabilities.
• Kleiner Perkins: Silicon Valley-based venture capital firm with parallel technology and healthcare/life sciences franchises, including legendary early investments in companies like Genentech and Google. Kleiner Perkins competes with Venrock for Bay Area AI, biotech, and health tech deals.
• Bessemer Venture Partners: Multi-stage US venture capital firm with a long healthcare and technology track record, including notable public-company alumni comparable to Venrock's. BVP's cross-stage approach and biotech/cloud investing focus overlap directly with Venrock's programs.
• ARCH Venture Partners: US venture capital firm focused on early-stage biotechnology, life sciences, and physical sciences, with comparable scale and stage to Venrock's healthcare practice. ARCH competes with Venrock Healthcare Capital Partners for founder-led biotech seed and Series A opportunities.
• OrbiMed Advisors: Healthcare-dedicated investment firm spanning venture, growth, and public equities, paralleling Venrock's combination of early-stage biotech investing and VHCP crossover capabilities. OrbiMed is a frequent co-investor and direct competitor in life sciences financings.
• RA Capital Management: Boston-based crossover fund focused on healthcare and biotech with both public-equity and late-stage private investing, structurally similar to Venrock's VHCP program. RA Capital appears in multiple recent syndicates alongside Venrock (cAMPfield, Adcendo) and competes for the same crossover opportunities.
• GV (Google Ventures): US venture capital arm of Alphabet investing across technology and life sciences at seed through growth stages. GV competes with Venrock in AI, biotech, and healthcare technology with comparable US footprint (Mountain View, Boston, London, New York).
• Frazier Life Sciences: Healthcare-focused venture capital firm investing across biotech and therapeutics at seed through public stages. Frazier led cAMPfield's $180M Series A that Venrock participated in and is a direct competitor in life sciences deal flow.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/Venrock
• LinkedInlinkedin.com/company/venrock
• Facebookfacebook.com/venrock

Revenue estimate

Valuation estimate

Number of profiles

Profiles20 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments912 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Venrock